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Although the number needed to treat (NNT), a bench-
mark to describe an incremental effect between two
medical treatments, is potentially useful on pharmaco-
economics, the theoretical investigations still remain to
overcome its limitations such as time-constraint. At the
5th ISPOR European Congress, we presented a speciﬁc
solution for the time-constraint, assuming that relative
risk reduction (RRR) is constant at any time. The con-
stant-RRR model could adjust the NNT onto any point
over the time axis. OBJECTIVE: To cope with a more
practical case of assumptions, we theoretically develop 
a formula for time-adjustment of the NNT based on a
variable-RRR model. METHOD: A constant-RRR model
is expanded into a variable-RRR model, considering the
efﬁcacies of both experimental and control regimens in a
clinical trial. Suppose that both of them exponentially
increase, asymptotically converging to one, as the fol-
lowing-up duration goes to inﬁnity. Furthermore, we
investigate what the standardization of the NNT means
in the variable-RRR model. RESULTS: In contrast with
a constant-RRR model, in which the NNT monotonously
decreases as the following-up duration becomes longer,
the NNT function in a variable-RRR model indicated a
U-shaped curve against the monotony. That is, the curve
of the NNT function monotonously decreases until a
certain point of following-up time, whereas it mono-
tonously increases after that point as the time becomes
longer. It implies that there exists a unique minimal NNT
in a variable-RRR model. CONCLUSION: Although the
NNT with a unit duration of following-up time such as
one year is recommended as the standard in a constant-
RRR model, we found the NNT function has a unique
minimal value in a variable-RRR model, which is theo-
retically informative for standardization of the NNT.
Considering such features with different assumptions 
on relative risk reduction, we can employ the NNT to 
be integrated in time-dependent model of pharmaco-
economic analysis.
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OBJECTIVES: To review current approaches to effec-
tiveness research. Study was conducted in two Phases: 1)
a review of general methodological designs of effective-
ness research in published literature; and 2) a synopsis 
of outcomes measured in identiﬁed studies from selected
therapeutic areas. METHODS: A literature search was
completed using MEDLINE, EMBASE, and HEED
sources from January 1990 to July 2002 using pre-
determined keywords. Phase 1 of the study summarized
articles on general methodological designs of effectiveness
studies; their commonalities, advantages, and limitations.
Criteria to evaluate effectiveness studies based on these
ﬁndings were then established. Effectiveness studies from
pre-determined therapeutic areas that ﬁt these criteria
were then selected for Phase 2 and their outcome mea-
sures were summarized. RESULTS: Of the 306 articles
found, 16 publications were selected for Phase 1 and 35
